+

WO1986003122A1 - Agents cicatrisants - Google Patents

Agents cicatrisants Download PDF

Info

Publication number
WO1986003122A1
WO1986003122A1 PCT/US1985/002205 US8502205W WO8603122A1 WO 1986003122 A1 WO1986003122 A1 WO 1986003122A1 US 8502205 W US8502205 W US 8502205W WO 8603122 A1 WO8603122 A1 WO 8603122A1
Authority
WO
WIPO (PCT)
Prior art keywords
platelet
blood
platelets
thrombin
rich plasma
Prior art date
Application number
PCT/US1985/002205
Other languages
English (en)
Inventor
David R. Knighton
Original Assignee
Curatech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curatech, Inc. filed Critical Curatech, Inc.
Priority to NL8520384A priority Critical patent/NL8520384A/nl
Priority to JP60505204A priority patent/JPH0720873B2/ja
Priority to AT85905980T priority patent/ATE78167T1/de
Priority to HU86420A priority patent/HUT42329A/hu
Priority to DE8585905980T priority patent/DE3586355T2/de
Publication of WO1986003122A1 publication Critical patent/WO1986003122A1/fr
Priority to NO862964A priority patent/NO170194C/no
Priority to SE8603228A priority patent/SE8603228D0/xx
Priority to FI863087A priority patent/FI85219C/fi
Priority to DK357386A priority patent/DK165169C/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0028—Polypeptides; Proteins; Degradation products thereof
    • A61L26/0033—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/64—Animal cells

Definitions

  • This invention relates to wound healing agents, specifically angiogenic and growth factors, their produc ⁇ tion from blood and their use to facilitate the healing of wounds.
  • Angiogenesis which is the proliferation and directed growth of capillary endothelium, along with fibroplasia and collagen synthesis are integral components of a host's response to wounding. The activation of plate-
  • X5 lets and the clotting cascade are among the first reactions to injury.
  • Platelets activated by thrombin release a mito- gen, or growth factor, for fibroblasts and smooth muscle cells and stimulate increased collagen synthesis by smooth
  • PDGF platelet-derived growth factor
  • Plate-Derived Growth Factor is a Chemoattrac- tant for Vascular Smooth Muscle Cells", Vol. 113, pp. 261- 266. The article is incorporated herein by reference.
  • a non-mitogenic substance, called angiogenic factor, is also produced by thrombin activated platelets
  • angiogenesis fac ⁇ tors are known including tumor, retinal and wound fluid angiogenesis factors. It is unknown whether all angiogene ⁇ sis factors share a common mechanism of action upon capillary endothelial cells.
  • a human angiogenic factor is produced from human foreskin fibroblasts in United States Patent 4,273,871 to Tolbert et al.
  • a publically available foreskin fibroblast cell line is utilized to produce an angiogenic factor.
  • platelet-derived growth factors are charac- terized and extracted for study by gel electrophoresis _ means.
  • Thrombin activated platelets have the capacity to stimulate angiogenesis, increased collagen synthesis and cell division and growth. It has been found that samples of whole blood may be utilized to prepare a platelet- enriched plasma, which when activated by thrombin, contains angiogenic and growth factors which may be used to speed the healing process of wounds. Blood is stabilized and centrifuged to obtain a platelet- ich plasma. The blood is stabilized- by mixing with citrate-phosphate-dextrose in a ratio of 1:5 (20% solution). The platelet- rich plasma (hereinafter PRP) is preferably centrifuged again until a high concentration of platelets is obtained. The platelets are then placed in a platelet buffer.
  • PRP platelet- rich plasma
  • the concentration of platelets should be at least 1,000,000 platelets per milliliter. Preferably, the concentration should be on the order of 1,000,000,000 platelets per milliliter.
  • Thrombin is added to the PRP in order to activate the platelets. Preferably, about 1 to about 10 units of thrombin are utilized per milliliter of PRP.
  • the thrombin- activated platelets release platelet derived growth factors (hereinafter PDGF) and platelet derived angiogenesis fac- tors (hereinafter PDAF).
  • PDGF platelet derived growth factors
  • PDAF platelet derived angiogenesis fac- tors
  • the activated PRP containing PDGF and PDAF is preferably added to a biologically compatible macromolecu- lar substance which acts as a carrier.
  • a biologically compatible macromolecu- lar substance which acts as a carrier.
  • the platelet free supernatant is mixed with the carrier.
  • a microcrystalline collagen such as Avitene® brand collagen as sold by FMC Corp., Avicel Dept. , Marcus Hook, PA 19061 is utilized as the biologically compatible carrier.
  • Micro- crystalline collagens are biologically compatible in the body.
  • Enough carrier is added to soak up all the platelet rich plasma that is obtained from the blood. For example, a 40ml blood sample would typically require about 25ml of carrier after enrichment.
  • the paste so obtained is pre ⁇ ferably stored on ice or in the refrigerator.
  • the pharmaceutical preparations for use as a wound dressing sold by Pharmacia Fine Chemicals, Inc. of Piscataway, New Jersey under the trademark Debrisan is a suitable carrier.
  • the activated PRP within the carrier may then be applied to a wound.
  • the highly enriched and active PDGF and PDAF therewithin assists in healing by proliferating and directing the growth of capillary endothelium, doubling the rate of collagen synthesis and by producing leukocyte chemotaxis. Mitogenic activity results in cellular divi ⁇ sion and growth to replace the lost tissue.
  • thrombin as a biologic release agent for platelet release.
  • Other biologic release agents known in the art includedi-ng collagen, ADP and serotonin, may be utilized instead of or in addition to thrombin to activate the platelets, although thrombin is preferred.
  • Blood obtained from the individual to be treated with the wound healing factors of the invention is stabilized in siliconized tubes containing acid-citrate dextrose (0.15M citrate, 2% glucose, pH 4.2) (hereinafter CPD) and is centrifuged in order to separate out the platelet-rich plasma therefrom. Forty to sixth milliliters of blood combined with 4-6ml of CPD is then centrifuged at about 135 x g for 20 minutes at about 4°C to obtain platelet-rich plasma. The platelet rich plasma is removed and placed into another steriie, 50ml tube. A platelet count is then taken. The CDP is utilized to prevent acti- vation of the clotting sequence by contact of the blood with the plastic in the syringe.
  • CPD acid-citrate dextrose (0.15M citrate, 2% glucose, pH 4.2)
  • the CPD is present in the syringe while the blood is withdrawn from the patient.
  • the blood is continuously mixed with the CPD to prevent coagu ⁇ lation.
  • the platelet- rich plasma in the tube is then centrifuged at 750 x g for 10 minutes at 4°C.
  • the platelet-free plasma is removed and discarded.
  • the platelet pellet is resuspended in a quantity of platelet buffer to produce a final ml.
  • a lower concentration of about a million platelets per ml is useful, but is less, preferred.
  • the platelet buffer utilized contains .05 M HEPES (N-2-hydroxyethylpiperazine- n-2-ethanesulfonic acid), 0.03 M glucose, 0.004 M KC1, 0.1 M NaCl and about 0.35% human serum albumin adjusted to a pH of about 6.5.
  • a sample is frozen at about -20°C for later testing of mitogenic activity. Another sample is streaked onto blood agar as a sterility test.
  • the platelet-rich plasma is the only blood frac ⁇ tion utilized in the processes and compositions of the invention.
  • the PRP is then activated with purified throm- bin at a rate of about 1 to about 10 units of thrombin per milliliter of PRP. Preferably, about 1 unit of thrombin per ml of platelet-rich plasma is utilized.
  • the activity of the thrombin coagulates the fibrinogen and activates platelets causing them to release alpha granules containing platelet-derived growth factor and platelet-derived angio ⁇ genesis factor.
  • the thrombin used was Thrombinar brand from Armour Pharmaceutical Co. of Kankakee, Illinois.
  • the platetlets and thrombin are allowed to incubate at room temperature for about 5-10 minutes.
  • the PRP is then subjected to a removal of plate ⁇ lets and fibrin by centrifugation.
  • the resulting super ⁇ natant contains both PDAF and PDGF after centrifuging at 950 x g for about 5 minutes at 4°C.
  • the pellet is discarded since the PDAF & PDGF have been extracted into the supernatant.
  • PDGF has been isolated and characterized. It is a protein of 30,000 molecular weight which breaks down into two molecular weight species of 15,000 and 14,000 molecular weight.
  • a carrier substance which is biologi ⁇ cally compatible and acts as a temporary "depot".
  • a macro- molecular substance such as microcrystalline collagen provides a suitable carrier.
  • An especially preferred carrier is Avitene ® brand microcrystalline collagen from FMC Corp., Avicel Dept., Marcus Hook, PA 19061.
  • the resultant composition is thicker and will tend to remain in position in contact with the wound.
  • DebrisanTM brand wound dressing which contains SepharoseTM brand beads, trademarks of Pharmacia Fine Chemicals, Inc. of Piscataway, New .Jersey, may be utilized as an alternative carrier.
  • about 8-10ml of supernatant per gram of carrier is used to produce a paste.
  • wound treating composition is by physically applying the material over an into the wound as in applying a medicated salve. Treatments should be repeated on a daily basis as long as the wound remains open.
  • a preferred treatment is to apply an approximately one mm thick dressing of the platelet factor/carrier co - plex to the wound in the morning. It is then dressed with a sterile, dry dressing. In the evening, the dressing is removed and the substance is removed by washing with sterile saline.
  • the compositions may treat internal wounds as well. Sutures may be impregnated with the wound treating compositions to speed internal healing.
  • the wound treating compositions may also be used in con- junction with biodegradable dressings, as a coating over implantable devices and biodegradable devices utilized in surgical procedures. Generally, any foreign body to be inserted into a patient may be coated with the composition to speed the healing process. Alternatively, the com- position may be applied over the damaged tissue directly.
  • a con ⁇ sistent source of the material may be obtained from washed, outdated human platelets.
  • the substances may also be uti ⁇ lized in veterinary applications by utilizing platelets derived from the animal itself or another animal within the same species.
  • Example I A patient having an open wound on the left foot following debride ent of dead tissue and transmetatarsal amputation was started on PDGF and PDAF obtained as described above from his own blood. After the treatment protocol , the wound was filled with new granulation tissue. A subsequent debridement showed completely covered metatar- sal bones and contracture of the sizable wound.
  • Example II A patient underwent amputation of his right great toe and was treated with standard therapy for three weeks without any granulation tissue accumulating within the wound. He was then started on the platelet factor therapy of the invention. After three weeks of treatment, the wound contracted approximately 30-40% and was healing rapidly.
  • Example III A patient having two large wounds on the medial and lateral aspect of his transmatatarsal amputation stump had been treated for four months without healing using con ⁇ ventional therapy.
  • the wound had cleared of an apparent infection and started producing granulation tissue.
  • a paste prepared from PRP at a concentration of about 10 ⁇ platelets/ml was combined with Avitene brand collagen.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Eye Examination Apparatus (AREA)

Abstract

Du plasma enrichi de plaquettes est produit à partir de sang. Les plaquettes sont activées avec de la thrombine, ce qui provoque la libération de facteurs de croissance et d'angiogénèse dérivés des plaquettes. Un porteur tel que le collagène microcristallin est ajouté pour produire un baume de traitement de blessures. Le composé est appliqué directement sur des blessures, amorce la guérison de blessures ou plaies ne cicatrisant pas, et accélère la cicatrisation normale en augmentant la vascularisation, en stimulant la mitose de fibroblastes et en augmentant la synthèse de collagène par les fibroblastes.
PCT/US1985/002205 1984-11-29 1985-11-08 Agents cicatrisants WO1986003122A1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
NL8520384A NL8520384A (nl) 1984-11-29 1985-11-08 Wondhelende middelen.
JP60505204A JPH0720873B2 (ja) 1984-11-29 1985-11-08 創傷治癒剤
AT85905980T ATE78167T1 (de) 1984-11-29 1985-11-08 Heilmittel fuer wunden.
HU86420A HUT42329A (en) 1984-11-29 1985-11-08 Process for producing compositions for curing wounds
DE8585905980T DE3586355T2 (de) 1984-11-29 1985-11-08 Heilmittel fuer wunden.
NO862964A NO170194C (no) 1984-11-29 1986-07-23 Fremgangsmaate for fremstilling av fysiologisk aktive saarhelingsstoffer
SE8603228A SE8603228D0 (sv) 1984-11-29 1986-07-25 Sarlekningsmedel
FI863087A FI85219C (fi) 1984-11-29 1986-07-28 Foerfarande foer framstaellning av ett fraon blodplaettar loesgjort material.
DK357386A DK165169C (da) 1984-11-29 1986-07-28 Anvendelse af stoffer fra blodplader til fremstilling af topiske saarhelingsmidler

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US67647184A 1984-11-29 1984-11-29
US676,471 1984-11-29
US78620685A 1985-10-10 1985-10-10
US786,206 1985-10-10

Publications (1)

Publication Number Publication Date
WO1986003122A1 true WO1986003122A1 (fr) 1986-06-05

Family

ID=27101561

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1985/002205 WO1986003122A1 (fr) 1984-11-29 1985-11-08 Agents cicatrisants

Country Status (16)

Country Link
EP (2) EP0202298B1 (fr)
AT (1) ATE78167T1 (fr)
AU (1) AU596954B2 (fr)
CA (1) CA1261259A (fr)
CH (1) CH673774A5 (fr)
DE (2) DE3590594T1 (fr)
DK (1) DK165169C (fr)
FI (1) FI85219C (fr)
GB (1) GB2248777B (fr)
HU (1) HUT42329A (fr)
IE (1) IE57894B1 (fr)
IL (1) IL77096A (fr)
NL (1) NL8520384A (fr)
NO (1) NO170194C (fr)
SE (1) SE8603228D0 (fr)
WO (1) WO1986003122A1 (fr)

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0322249A2 (fr) * 1987-12-22 1989-06-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Méthodes de préparation et compositions pharmaceutiques contenant des dérivés du collagène
WO1990000059A1 (fr) * 1988-06-28 1990-01-11 Girolamo Sirchia Procede et recipient servant a la preparation et au stockage de concentres de plaquettes
US4900541A (en) * 1988-05-06 1990-02-13 Govier William C Sunscreen composition
EP0417818A1 (fr) * 1989-09-15 1991-03-20 Curative Technologies, Inc. Sélection quantitative de sécrétions plaquettaires pour un traitement efficace des tissus
US5045633A (en) * 1985-02-25 1991-09-03 Zymogenetics, Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US5187263A (en) * 1984-10-12 1993-02-16 Zymogenetics, Inc. Expression of biologically active PDGE analogs in eucaryotic cells
WO1993006872A1 (fr) * 1991-10-11 1993-04-15 Genetics Institute, Inc. Formulations de caillot de sang-matrice polymere d'apport de proteines osteogenes
EP0564502A1 (fr) * 1990-11-27 1993-10-13 American National Red Cross Compositions contenant un agent de fermeture des tissus et des facteurs de croissance, qui accelerent la cicatrisation
FR2696095A1 (fr) * 1992-09-30 1994-04-01 Inoteb Colle biologique à base de protéines coagulables par la thrombine, enrichie en facteurs plaquettaires, sa préparation et son application.
US5399361A (en) * 1992-05-01 1995-03-21 Amgen Inc. Collagen-containing sponges as drug delivery compositions for proteins
WO1995015763A1 (fr) * 1993-12-08 1995-06-15 Universite De Montreal Procede de preparation d'un extrait de serum et de facteur de croissance plaquettaire
US5428010A (en) * 1984-10-12 1995-06-27 Zymogenetics, Inc. Biologically active B-chain homodimers
US5498600A (en) * 1984-10-12 1996-03-12 Zymogenetics, Inc. Biologically active mosaic proteins
WO1996027397A1 (fr) * 1995-03-03 1996-09-12 Quantic Biomedical Partners Colle plaquettaire, agent d'obturation de plaies
WO1996037601A1 (fr) * 1995-05-24 1996-11-28 Cellfactors Plc Agents de differenciation cellulaire
US5599558A (en) * 1989-09-15 1997-02-04 Curative Technologies, Inc. Selecting amounts of platelet releasate for efficacious treatment of tissue
US5618663A (en) * 1992-06-05 1997-04-08 Inoteb Device for producing a supernatant of activated thrombocytes, method for implementing the device and supernatant obtained
WO1997034614A1 (fr) * 1996-03-20 1997-09-25 Theratechnologies Inc. Procede de preparation d'extrait de facteurs de croissance plaquettaire pour preparations cicatrisantes
US5814602A (en) * 1988-03-17 1998-09-29 Novo Nordisk A/S Heparin-binding proteins
US6010627A (en) * 1995-06-06 2000-01-04 Quantic Biomedical Partners Device for concentrating plasma
US6054122A (en) * 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US6117425A (en) * 1990-11-27 2000-09-12 The American National Red Cross Supplemented and unsupplemented tissue sealants, method of their production and use
US6120520A (en) * 1997-05-27 2000-09-19 Angiotrax, Inc. Apparatus and methods for stimulating revascularization and/or tissue growth
US6197325B1 (en) 1990-11-27 2001-03-06 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
EP1091735A1 (fr) * 1998-06-22 2001-04-18 Autologous Wound Therapy, Inc. Cicatrisant pour blessures ameliore a l'aide de plaquettes enrichies
US6432119B1 (en) 1999-03-17 2002-08-13 Angiotrax, Inc. Apparatus and methods for performing percutaneous myocardial revascularization and stimulating angiogenesis using autologous materials
US6559119B1 (en) 1990-11-27 2003-05-06 Loyola University Of Chicago Method of preparing a tissue sealant-treated biomedical material
US6762336B1 (en) 1998-01-19 2004-07-13 The American National Red Cross Hemostatic sandwich bandage
EP1507543A1 (fr) * 2002-05-09 2005-02-23 Medigenes Composition pharmaceutique destinee au traitement de plaies et contenant du plasma ou du serum sanguins
WO2005105121A1 (fr) * 2004-05-05 2005-11-10 Synthes Gmbh Utilisation de plaquettes ou de plasma riche en plaquettes (prp)
US7112342B2 (en) 1998-06-22 2006-09-26 Cytomedix, Inc. Enriched platelet wound healant
US7189410B1 (en) 1990-11-27 2007-03-13 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
USRE43300E1 (en) 1996-12-02 2012-04-03 Abbott Cardiovascular Systems Inc. Apparatus having stabilization members for percutaneously performing surgery and methods of use
US8268362B2 (en) 1997-11-12 2012-09-18 Bio-Products & Bio-Engineering Aktiengesellschaft Medicinal product for the promotion of wound healing
US8293530B2 (en) 2006-10-17 2012-10-23 Carnegie Mellon University Method and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom
US8529958B2 (en) 2006-10-17 2013-09-10 Carmell Therapeutics Corporation Methods and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom
US8529960B2 (en) 2002-03-18 2013-09-10 Carnell Therapeutics Corporation Methods and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom
US8679528B2 (en) 2002-09-10 2014-03-25 American National Red Cross Hemostatic dressing
USRE45638E1 (en) 1996-12-02 2015-08-04 Abbott Cardiovascular Systems Inc. Apparatus for percutaneously performing myocardial revascularization having means for sensing tissue parameters and method of use
US9131929B2 (en) 2007-08-06 2015-09-15 Stb, Ltd. Methods and dressings for sealing internal injuries
CN114831770A (zh) * 2022-05-20 2022-08-02 上海浦灵生物科技有限公司 一种肺动脉高压非人灵长类动物模型及其构建方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0637450A3 (fr) * 1993-08-04 1995-04-05 Collagen Corp Méthode et composition pour revigorer le tissu cicatriciel.
US6117444A (en) * 1997-04-10 2000-09-12 Brigham & Women's Hospital Polyethylene glycol/microfibrillar collagen composite serves as a resorbable hemostatic agent
US20200208110A1 (en) 2018-11-30 2020-07-02 Cellphire, Inc. PLATELETS LOADED WITH mRNA
EP3886879A4 (fr) 2018-11-30 2022-12-07 Cellphire Inc. Plaquettes en tant qu'agents de livraison
KR20220016092A (ko) 2019-05-03 2022-02-08 셀파이어, 인크. 혈액 생성물을 생산하기 위한 물질 및 방법
US20210299179A1 (en) 2020-02-04 2021-09-30 Cellphire, Inc. Methods of treating congenital hemophilia with anti-fibrinolytic loaded platelets
EP4013496A4 (fr) 2019-08-16 2023-10-18 Cellphire Inc. Thrombosomes en tant qu'agent désactivateur d'antiagrégant plaquettaire

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3628974A (en) * 1966-05-27 1971-12-21 Fmc Corp Microcrystalline collagen, an ionizable partial salt of collagen and foods, pharmaceuticals and cosmetics containing same
US4479896A (en) * 1981-12-11 1984-10-30 Antoniades Harry N Method for extraction localization and direct recovery of platelet derived growth factor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2472385A1 (fr) * 1979-12-27 1981-07-03 Sederma Sa Nouveaux extraits biologiques utilisables en cosmetologie, et procedes d'obtention de ces extraits
FR2533438B2 (fr) * 1979-12-27 1986-03-07 Sederma Sarl Utilisation en cosmetologie des facteurs de croissance et d'extraits biologiques contenant ceux-ci
DE3110560A1 (de) * 1981-03-18 1982-10-14 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen "angiotropine der leukozyten und des entzuendungsgewebes: eine neue klasse natuerlicher chemotropischer mitogene fuer das richtungswachstum von blutgefaessen und zur neovaskularisierung von geweben"
US4444760A (en) * 1983-06-17 1984-04-24 Merck & Co., Inc. Purification and characterization of a protein fibroblast growth factor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3628974A (en) * 1966-05-27 1971-12-21 Fmc Corp Microcrystalline collagen, an ionizable partial salt of collagen and foods, pharmaceuticals and cosmetics containing same
US4479896A (en) * 1981-12-11 1984-10-30 Antoniades Harry N Method for extraction localization and direct recovery of platelet derived growth factor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Annals of Surgery Vol. 196 No. 4 (Oct. 1982) KNIGHTON et al, Role of Platelets and Fibrin in the Healing Sequence, pages 379-388 *

Cited By (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5498600A (en) * 1984-10-12 1996-03-12 Zymogenetics, Inc. Biologically active mosaic proteins
US6004929A (en) * 1984-10-12 1999-12-21 Zymogenetics, Inc. Biologically active PDGF A-chain homodimers
US5428010A (en) * 1984-10-12 1995-06-27 Zymogenetics, Inc. Biologically active B-chain homodimers
US5187263A (en) * 1984-10-12 1993-02-16 Zymogenetics, Inc. Expression of biologically active PDGE analogs in eucaryotic cells
US5045633A (en) * 1985-02-25 1991-09-03 Zymogenetics, Inc. Expression of biologically active PDGF analogs in eucaryotic cells
EP0322249A3 (en) * 1987-12-22 1990-03-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Collagen products, processes for the preparation thereof and pharmaceutical compositions containing the same
US5073378A (en) * 1987-12-22 1991-12-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Processes for the preparation of storage stable collagen products
EP0322249A2 (fr) * 1987-12-22 1989-06-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Méthodes de préparation et compositions pharmaceutiques contenant des dérivés du collagène
US5814602A (en) * 1988-03-17 1998-09-29 Novo Nordisk A/S Heparin-binding proteins
US4900541A (en) * 1988-05-06 1990-02-13 Govier William C Sunscreen composition
WO1990000059A1 (fr) * 1988-06-28 1990-01-11 Girolamo Sirchia Procede et recipient servant a la preparation et au stockage de concentres de plaquettes
FR2652088A1 (fr) * 1989-09-15 1991-03-22 Curative Tech Inc Procede de preparation d'un produit a base de substance liberee par les plaquettes, et produit obtenu par ce procede.
EP0417818A1 (fr) * 1989-09-15 1991-03-20 Curative Technologies, Inc. Sélection quantitative de sécrétions plaquettaires pour un traitement efficace des tissus
US5599558A (en) * 1989-09-15 1997-02-04 Curative Technologies, Inc. Selecting amounts of platelet releasate for efficacious treatment of tissue
EP1142581A2 (fr) * 1990-11-27 2001-10-10 American National Red Cross Compositions contenant un agent de scellement tissulaire et des facteurs de croissance, qui accélérent la cicatrisation
US7196054B1 (en) 1990-11-27 2007-03-27 The American National Red Cross Methods for treating wound tissue and forming a supplemented fibrin matrix
US6117425A (en) * 1990-11-27 2000-09-12 The American National Red Cross Supplemented and unsupplemented tissue sealants, method of their production and use
US7189410B1 (en) 1990-11-27 2007-03-13 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US6054122A (en) * 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
USRE39321E1 (en) * 1990-11-27 2006-10-03 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US7208179B1 (en) 1990-11-27 2007-04-24 The American National Red Cross Methods for treating disease and forming a supplemented fibrin matrix
USRE39298E1 (en) * 1990-11-27 2006-09-19 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US7229959B1 (en) 1990-11-27 2007-06-12 The American National Red Cross Supplemented fibrin matrix delivery systems
US6197325B1 (en) 1990-11-27 2001-03-06 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
USRE39192E1 (en) * 1990-11-27 2006-07-18 American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US6559119B1 (en) 1990-11-27 2003-05-06 Loyola University Of Chicago Method of preparing a tissue sealant-treated biomedical material
EP0564502A4 (fr) * 1990-11-27 1994-01-05 American National Red Cross
EP0564502A1 (fr) * 1990-11-27 1993-10-13 American National Red Cross Compositions contenant un agent de fermeture des tissus et des facteurs de croissance, qui accelerent la cicatrisation
EP1142581A3 (fr) * 1990-11-27 2002-09-11 American National Red Cross Compositions contenant un agent de scellement tissulaire et des facteurs de croissance, qui accélérent la cicatrisation
WO1993006872A1 (fr) * 1991-10-11 1993-04-15 Genetics Institute, Inc. Formulations de caillot de sang-matrice polymere d'apport de proteines osteogenes
US5512301A (en) * 1992-05-01 1996-04-30 Amgen Inc. Collagen-containing sponges as drug delivery compositions for proteins
US5399361A (en) * 1992-05-01 1995-03-21 Amgen Inc. Collagen-containing sponges as drug delivery compositions for proteins
US5618663A (en) * 1992-06-05 1997-04-08 Inoteb Device for producing a supernatant of activated thrombocytes, method for implementing the device and supernatant obtained
US5589462A (en) * 1992-09-30 1996-12-31 Inoteb Method of preparing a biological adhesive enriched with platelet factors, and application
FR2696095A1 (fr) * 1992-09-30 1994-04-01 Inoteb Colle biologique à base de protéines coagulables par la thrombine, enrichie en facteurs plaquettaires, sa préparation et son application.
WO1994007548A1 (fr) * 1992-09-30 1994-04-14 Inoteb Procede de preparation d'une colle biologique enrichie en facteurs plaquettaires et application
WO1995015763A1 (fr) * 1993-12-08 1995-06-15 Universite De Montreal Procede de preparation d'un extrait de serum et de facteur de croissance plaquettaire
WO1996027397A1 (fr) * 1995-03-03 1996-09-12 Quantic Biomedical Partners Colle plaquettaire, agent d'obturation de plaies
US5733545A (en) * 1995-03-03 1998-03-31 Quantic Biomedical Partners Platelet glue wound sealant
WO1996037601A1 (fr) * 1995-05-24 1996-11-28 Cellfactors Plc Agents de differenciation cellulaire
US6342157B1 (en) 1995-06-06 2002-01-29 Interpore Orthopedics, Inc. Device and method for concentrating plasma
US6010627A (en) * 1995-06-06 2000-01-04 Quantic Biomedical Partners Device for concentrating plasma
WO1997034614A1 (fr) * 1996-03-20 1997-09-25 Theratechnologies Inc. Procede de preparation d'extrait de facteurs de croissance plaquettaire pour preparations cicatrisantes
AU725091B2 (en) * 1996-03-20 2000-10-05 Theratechnologies Inc. Process for the preparation of platelet growth factors extract for wound healing compositions
USRE43300E1 (en) 1996-12-02 2012-04-03 Abbott Cardiovascular Systems Inc. Apparatus having stabilization members for percutaneously performing surgery and methods of use
USRE42959E1 (en) 1996-12-02 2011-11-22 Abbott Cardiovascular Systems Inc. Apparatus and methods for stimulating revascularization and/or tissue growth
USRE45638E1 (en) 1996-12-02 2015-08-04 Abbott Cardiovascular Systems Inc. Apparatus for percutaneously performing myocardial revascularization having means for sensing tissue parameters and method of use
US6120520A (en) * 1997-05-27 2000-09-19 Angiotrax, Inc. Apparatus and methods for stimulating revascularization and/or tissue growth
US8268362B2 (en) 1997-11-12 2012-09-18 Bio-Products & Bio-Engineering Aktiengesellschaft Medicinal product for the promotion of wound healing
US6762336B1 (en) 1998-01-19 2004-07-13 The American National Red Cross Hemostatic sandwich bandage
EP1091735A4 (fr) * 1998-06-22 2004-05-06 Cytomedix Inc Cicatrisant pour blessures ameliore a l'aide de plaquettes enrichies
US7112342B2 (en) 1998-06-22 2006-09-26 Cytomedix, Inc. Enriched platelet wound healant
EP1091735A1 (fr) * 1998-06-22 2001-04-18 Autologous Wound Therapy, Inc. Cicatrisant pour blessures ameliore a l'aide de plaquettes enrichies
US6432119B1 (en) 1999-03-17 2002-08-13 Angiotrax, Inc. Apparatus and methods for performing percutaneous myocardial revascularization and stimulating angiogenesis using autologous materials
US8529960B2 (en) 2002-03-18 2013-09-10 Carnell Therapeutics Corporation Methods and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom
EP1507543A4 (fr) * 2002-05-09 2006-07-26 Cambridgemed Inc Composition pharmaceutique destinee au traitement de plaies et contenant du plasma ou du serum sanguins
AU2003230321B8 (en) * 2002-05-09 2009-07-30 Medigenes A pharmaceutical composition for treatment of wounds containing blood plasma or serum
US8017157B2 (en) 2002-05-09 2011-09-13 Osiris Therapeutics, Inc. Method of treating a wound with acidified plasma or serum
EP1507543A1 (fr) * 2002-05-09 2005-02-23 Medigenes Composition pharmaceutique destinee au traitement de plaies et contenant du plasma ou du serum sanguins
US8679528B2 (en) 2002-09-10 2014-03-25 American National Red Cross Hemostatic dressing
WO2005105121A1 (fr) * 2004-05-05 2005-11-10 Synthes Gmbh Utilisation de plaquettes ou de plasma riche en plaquettes (prp)
US8529961B2 (en) 2006-10-17 2013-09-10 Carmell Therapeutics Corporation Methods and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom
US8529959B2 (en) 2006-10-17 2013-09-10 Carmell Therapeutics Corporation Methods and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom
US8529958B2 (en) 2006-10-17 2013-09-10 Carmell Therapeutics Corporation Methods and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom
US8911789B2 (en) 2006-10-17 2014-12-16 Carnegie Mellon University Methods and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom
US8293530B2 (en) 2006-10-17 2012-10-23 Carnegie Mellon University Method and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom
US9364503B2 (en) 2006-10-17 2016-06-14 Carmell Therapeutics Corporation Methods and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom
US9131929B2 (en) 2007-08-06 2015-09-15 Stb, Ltd. Methods and dressings for sealing internal injuries
CN114831770A (zh) * 2022-05-20 2022-08-02 上海浦灵生物科技有限公司 一种肺动脉高压非人灵长类动物模型及其构建方法

Also Published As

Publication number Publication date
FI85219B (fi) 1991-12-13
FI863087L (fi) 1986-07-28
DK357386D0 (da) 1986-07-28
GB8617658D0 (en) 1986-08-28
NL8520384A (nl) 1986-10-01
CH673774A5 (fr) 1990-04-12
DK165169C (da) 1993-03-01
DK165169B (da) 1992-10-19
DE3586355T2 (de) 1993-01-14
FI863087A0 (fi) 1986-07-28
EP0383363A3 (fr) 1990-10-03
GB2248777B (en) 1993-06-30
DE3586355D1 (de) 1992-08-20
EP0202298B1 (fr) 1992-07-15
DK357386A (da) 1986-07-28
AU5094985A (en) 1986-06-18
IL77096A (en) 1993-01-31
FI85219C (fi) 1992-03-25
CA1261259A (fr) 1989-09-26
NO862964L (no) 1986-07-23
HUT42329A (en) 1987-07-28
IE57894B1 (en) 1993-05-05
NO170194C (no) 1992-09-23
SE8603228L (sv) 1986-07-25
ATE78167T1 (de) 1992-08-15
NO170194B (no) 1992-06-15
IE852810L (en) 1986-05-29
GB2248777A (en) 1992-04-22
NO862964D0 (no) 1986-07-23
SE8603228D0 (sv) 1986-07-25
EP0202298A4 (fr) 1988-07-04
EP0383363A2 (fr) 1990-08-22
AU596954B2 (en) 1990-05-24
EP0202298A1 (fr) 1986-11-26
DE3590594T1 (fr) 1987-01-29

Similar Documents

Publication Publication Date Title
EP0202298B1 (fr) Agents cicatrisants
US5178883A (en) Method for promoting hair growth
US5165938A (en) Wound healing agents derived from platelets
US4957742A (en) Method for promoting hair growth
US7208179B1 (en) Methods for treating disease and forming a supplemented fibrin matrix
USRE39321E1 (en) Supplemented and unsupplemented tissue sealants, methods of their production and use
US6559119B1 (en) Method of preparing a tissue sealant-treated biomedical material
US20030007957A1 (en) Novel wound healing composition not containing bovine-derived activating reagents
US20040197319A1 (en) Wound healing composition derived from low platelet concentration plasma
WO2008022651A1 (fr) Procédé et dispositif de préparation de plasma riche en plaquettes pour utilisation impromptue et sa combinaison avec des cellules cutanées et osseuses
WO1996040174A1 (fr) Produits d'obturation tissulaires completes et non completes, leurs procedes de production et d'utilisation
KR20010071577A (ko) 혈소판이 풍부한 개선된 상처 치유제
US20030152639A1 (en) Novel wound healing composition not containing bovine-derived activating reagents
JPH04504569A (ja) 血小板抽出物の塗布による毛の成長促進法
JP3993981B2 (ja) 改良された濃縮血小板創傷治癒剤に対する特許の適用
JPH0720873B2 (ja) 創傷治癒剤
JPH11246420A (ja) 創傷治癒促進剤
RU2805189C1 (ru) Способ аутодермопластики
WO1994009800A1 (fr) Procede favorisant la cicatrisation des plaies et compositions utilisees a cet effet
MD1179Z (ro) Metodă de tratament al ulcerelor trofice

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BR CH DE DK FI GB HU JP KP LU NL NO SE SU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1985905980

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 863087

Country of ref document: FI

ENP Entry into the national phase

Ref document number: 1985 9049

Country of ref document: AT

Date of ref document: 19860605

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1985905980

Country of ref document: EP

RET De translation (de og part 6b)

Ref document number: 3590594

Country of ref document: DE

Date of ref document: 19870129

WWE Wipo information: entry into national phase

Ref document number: 3590594

Country of ref document: DE

WWG Wipo information: grant in national office

Ref document number: 863087

Country of ref document: FI

WWG Wipo information: grant in national office

Ref document number: 1985905980

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载